A famotidin alkalmazása fekélybetegségben.

Translated title of the contribution: Famotidine in the treatment of gastroduodenal ulcer

Research output: Contribution to journalArticle

Abstract

In the treatment of gastroduodenal ulceration both the reduction of gastric acidity and the defence of mucosal membrane have an important role. The development of H2-receptor antagonist has brought a significant change in the decrease of acid secretion in the last two decades. After the development and clinical application of cimetidine and ranitidine, a newly developed H2-receptor blocker, the famotidine has been introduced. Both the pharmacological and clinical investigations demonstrated the efficacy of this drug either in gastric or in duodenal ulcerations. The clinical pharmacological studies expressed mainly the advantageous character, that in the achievement of therapeutic effect smaller quantity is required than that of the other H2-receptor blocker. In the dosage of 40 mg (bedtime once, or daily twice) significantly decreases the basal and the stimulated gastric acid secretion as well as the daily and the nocturnal pains of the patients. Experience for several years have demonstrated efficacy in a 20 mg dosage of this drug in defence of ulceration relapses. It can be very well tolerated without significant side effects. Its long term applications is safety and economically advantageous.

Original languageHungarian
Pages (from-to)2299-2304
Number of pages6
JournalOrvosi Hetilap
Volume135
Issue number42
Publication statusPublished - Oct 16 1994

Fingerprint

Famotidine
Histamine H2 Receptors
Peptic Ulcer
Stomach
Pharmacology
Ranitidine
Gastric Acid
Cimetidine
Therapeutic Uses
Pharmaceutical Preparations
Therapeutics
Safety
Recurrence
Pain
Acids
Membranes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A famotidin alkalmazása fekélybetegségben. / Lengyel, G.; Fehér, J.

In: Orvosi Hetilap, Vol. 135, No. 42, 16.10.1994, p. 2299-2304.

Research output: Contribution to journalArticle

@article{942fc501be7944efa6a46a6437618af2,
title = "A famotidin alkalmaz{\'a}sa fek{\'e}lybetegs{\'e}gben.",
abstract = "In the treatment of gastroduodenal ulceration both the reduction of gastric acidity and the defence of mucosal membrane have an important role. The development of H2-receptor antagonist has brought a significant change in the decrease of acid secretion in the last two decades. After the development and clinical application of cimetidine and ranitidine, a newly developed H2-receptor blocker, the famotidine has been introduced. Both the pharmacological and clinical investigations demonstrated the efficacy of this drug either in gastric or in duodenal ulcerations. The clinical pharmacological studies expressed mainly the advantageous character, that in the achievement of therapeutic effect smaller quantity is required than that of the other H2-receptor blocker. In the dosage of 40 mg (bedtime once, or daily twice) significantly decreases the basal and the stimulated gastric acid secretion as well as the daily and the nocturnal pains of the patients. Experience for several years have demonstrated efficacy in a 20 mg dosage of this drug in defence of ulceration relapses. It can be very well tolerated without significant side effects. Its long term applications is safety and economically advantageous.",
author = "G. Lengyel and J. Feh{\'e}r",
year = "1994",
month = "10",
day = "16",
language = "Hungarian",
volume = "135",
pages = "2299--2304",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "42",

}

TY - JOUR

T1 - A famotidin alkalmazása fekélybetegségben.

AU - Lengyel, G.

AU - Fehér, J.

PY - 1994/10/16

Y1 - 1994/10/16

N2 - In the treatment of gastroduodenal ulceration both the reduction of gastric acidity and the defence of mucosal membrane have an important role. The development of H2-receptor antagonist has brought a significant change in the decrease of acid secretion in the last two decades. After the development and clinical application of cimetidine and ranitidine, a newly developed H2-receptor blocker, the famotidine has been introduced. Both the pharmacological and clinical investigations demonstrated the efficacy of this drug either in gastric or in duodenal ulcerations. The clinical pharmacological studies expressed mainly the advantageous character, that in the achievement of therapeutic effect smaller quantity is required than that of the other H2-receptor blocker. In the dosage of 40 mg (bedtime once, or daily twice) significantly decreases the basal and the stimulated gastric acid secretion as well as the daily and the nocturnal pains of the patients. Experience for several years have demonstrated efficacy in a 20 mg dosage of this drug in defence of ulceration relapses. It can be very well tolerated without significant side effects. Its long term applications is safety and economically advantageous.

AB - In the treatment of gastroduodenal ulceration both the reduction of gastric acidity and the defence of mucosal membrane have an important role. The development of H2-receptor antagonist has brought a significant change in the decrease of acid secretion in the last two decades. After the development and clinical application of cimetidine and ranitidine, a newly developed H2-receptor blocker, the famotidine has been introduced. Both the pharmacological and clinical investigations demonstrated the efficacy of this drug either in gastric or in duodenal ulcerations. The clinical pharmacological studies expressed mainly the advantageous character, that in the achievement of therapeutic effect smaller quantity is required than that of the other H2-receptor blocker. In the dosage of 40 mg (bedtime once, or daily twice) significantly decreases the basal and the stimulated gastric acid secretion as well as the daily and the nocturnal pains of the patients. Experience for several years have demonstrated efficacy in a 20 mg dosage of this drug in defence of ulceration relapses. It can be very well tolerated without significant side effects. Its long term applications is safety and economically advantageous.

UR - http://www.scopus.com/inward/record.url?scp=0028775348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028775348&partnerID=8YFLogxK

M3 - Article

VL - 135

SP - 2299

EP - 2304

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 42

ER -